First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives
Trial Focused On Hispanic, Black And Native Americans
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
You may also be interested in...
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.
South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.